In this regard, recent studies suggest the potential utility of IKK inhibitors to enhance the response to cancer immunotherapies since NF-ĸB signaling can promote PD-L1 expression at both the transcriptional and post-transcriptional level [114]. The gene discussed is CD274; the disease is cancer.